Skip to main content
All lobbying filings

ASSOCIATION OF CANCER CARE CENTERS (FKA ASSOCIATION OF COMMUNITY CANCER CENTERS)

Lobbying for ASSOCIATION OF CANCER CARE CENTERS (FKA ASSOCIATION OF COMMUNITY CANCER CENTERS)

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · Maryland · House · Senate · $10,000.00 expenses · posted Jul 20, 2026

Official filing document

 Bills named in this filing 14
  • S 1816
    Improving Seniors’ Timely Access to Care Act of 2025
  • HR 3514
    Improving Seniors’ Timely Access to Care Act of 2025
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • HR 6718
    Professional Student Degree Act
  • HR 5509
    Safe Step Act
  • S 2903
    Safe Step Act
  • HR 2120
    ROCR Value Based Program Act
  • S 1031
    ROCR Value Based Program Act
  • S 2793
    Ensuring Access to Essential Providers Act of 2025
  • S 3607
    Access to Genetic Counselor Services Act of 2026
  • HR 6280
    Access to Genetic Counselor Services Act of 2025
  • HR 8839
    Lainie Jones Comprehensive Cancer Survivorship Act of 2026
  • HR 3521
    Clinical Trial Modernization Act
  • S 4440
    Clinical Trial Modernization Act
 Lobbying activity 1
Health Issues

Health care priorities of ACCC: 1) Prior authorization (Including: Improving Seniors Timely Access to Care Act of 2025 (S.1816/ H.R. 3514); 2) Oncology drug and medical supply shortages; 3) Financial toxicity for cancer patients; 4) Drug Pricing: Inflation Reduction Act implementation, Senate Finance Minority Drug Pricing RFI, and especially Protecting Patient Access to Cancer and Complex Therapies Act (H.R.4299); 5) Reducing Physician Payment Reimbursement Cuts; 6) Healthcare Workforce improvement, including re: streamlining visa processing and administration for international medical professionals, graduates, and students; 7) H.R. 6718 the Professional Student Degree Act; 8) Preserve Medicaid coverage for caregivers and other beneficiaries (mitigate potential impact of One Big Beautiful Bill Act (OBBBA) implementation on their coverage); 9) Safe Step Act (H.R. 5509/S. 2903); 10) Radiation Oncology Case Rate (ROCR) Value Based Program Act(H.R. 2120/S.1031); 11) Issues related to coverage (including renewal of ACA subsidies and mitigating impact of Medicaid changes in OBBBA); 12) Ensuring Access to Essential Providers Act of 2025 (S. 2793); 13) Access to Genetic Counselor Services Act (S. 3607/H.R. 6280); 14) Request to Designate April as Cancer Prevention and Early Detection month; 15) Modernize incentives for Advanced Alternative Payment Models (APMs); 16) Stabilize physician payment system and prepare for APMs; 17) Leverage the CMS Innovation Center; 18) Fiscal Year 2027 appropriations for these family caregiver support programs: National Family Caregiver Support Program, Lifespan Respite Care Program, Native American Caregiver Support Services, National Strategy Demonstration Grants; 19) FY 2027 appropriations funding recommendations in support of the Department of Veterans Affairs (VA) Medical and Prosthetic Research Program, funding to address VA research infrastructure deficiencies, and dedicated funding for VA research information technology modernization; 20) Appropriations for NIH funding; 21) Supportive cancer care, including discussion of federal legislation, such as the Lainie Jones Comprehensive Cancer Survivorship Act of 2026 (HR 8839)(not yet ACCC endorsed); 22) Clinical Trial Modernization Act (HR 3521/S. 4440); 23) 340B program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem